Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Fuji Pharma Shooting for 2.6-Fold Sales Increase by 2030: President
Fuji Pharma is aiming to ramp up its group sales by 2.6-fold to 100 billion yen by 2030, versus 37.9 billion yen in the year ended September 2018, as it expects its recent partnership with Iceland-based Alvotech to buoy its…
To read the full story
Related Article
- Japan’s First Stelara Biosimilar to Skip November Listing on Risk of Import Delays: Fuji Pharma
November 14, 2023
- Trader Mitsui’s Iwai Picked for Top Job at Fuji Pharma
October 7, 2019
- Fuji Pharma Invests US$50 Million in Alvotech to Boost Biosimilar Business in Japan
December 21, 2018
- Fuji Pharma to Bolster Biosimilar Business as New Core
November 20, 2018
- Fuji Pharma Poised to Develop New Biosimilar in Women’s Health/Acute Care
July 19, 2018
BUSINESS
- Recordati Urges Rethink of Zero-Premium Rule on Cost Disclosure
August 31, 2026
- Sumitomo Pharma Goes Global with Adjuvants, Targets 100 Billion Yen
August 31, 2026
- Shionogi to Get US$36.9 Million as US Govt Procures Fetroja
August 31, 2026
- Daiichi’s CD25-Directed ADC DS1025 Enters Clinic
August 31, 2026
- Bayer Files Kerendia in Japan for Broader CKD Use
August 31, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…